FDA Advisers Recommend Geron's Imetelstat for Anemia in Blood Cancer Patients
Thursday, 14 March 2024, 21:37
FDA Advisers Support Geron's Imetelstat
Advisers to the U.S. Food and Drug Administration have shown confidence in Geron's blood disorder drug, imetelstat. The votes in favor of the drug's benefits outweighing the associated risks indicate a positive outlook for its future use.
Panel Vote and Findings
- The panel voted 12-2 in favor of imetelstat's benefits.
- The risks and toxicities of the treatment were deemed manageable.
Geron's imetelstat could potentially offer improved treatment options for patients with transfusion-dependent anemia in myelodysplastic syndromes (MDS).
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.